Year: 2024
Type: article
Abstract: Inpatients with schizophrenia who switched from antipsychotic polypharmacy to monotherapy experienced significantly reduced side effects, including extrapyramidal symptoms and metabolic effects, an open‐label trial has found. The vast majority of patients in the study's switch group stopped taking a first‐generation antipsychotic and continued on their second‐generation drug. Study results were published online Sept. 16, 2024, in Schizophrenia Research.
DOI: 10.1002/pu.31250
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4404772646